Article by Dr. Thomas Burnell and Dr. Bethany Turner

Next Lesson - Artery and Vein Disease

Cardiovascular System


Contents

Abstract

  • Heart failure is the inability of the heart to meet the demands of the body.
  • Ejection fraction is the proportion of blood the ventricle pumps out with each beat. Heart failure can be divided into reduced ejection fraction and preserved ejection fraction, with a mildly reduced group in between. Reduced ejection fraction is often caused by ischaemic heart disease (a poor blood supply to the heart muscle). Preserved ejection fraction is often caused by hypertension (high blood pressure).
  • The symptoms of right sided heart failure are based around blood building up in the systemic circulation (e.g. peripheral oedema). Those of left sided heart failure are to do with blood building up in the pulmonary circulation (e.g. orthopnoea, breathlessness on lying flat).
  • Treatment of heart failure is focused on reducing symptoms and, where possible, improving prognosis.

Core

Heart failure is the inability of the heart to meet the body’s demands. It is a clinical syndrome (a recognised pattern of symptoms and signs) caused by a structural or functional abnormality of the heart. This leads to raised pressures inside the heart and/or inadequate cardiac output (CO), at rest or during exercise. The result can be tissue hypoperfusion (too little blood flow to the tissues) and tissue congestion (fluid backing up in the tissues).

There are many causes of heart failure, including:

  • Ischaemic heart disease - this causes myocardial damage which causes myocardial dysfunction, reducing the cardiac output.
  • Hypertension - increases the after-load (the pressure the ventricle has to pump against). This causes the ventricles to undergo hypertrophy in order to generate more force to pump blood out against the higher pressure.
    • The thickened myocardium results in the heart being less efficient at pumping blood, as there is reduced space in the ventricle, reducing the amount of filling. 
  • Aortic stenosis (narrowing of the aortic valve) - increases the after-load on the ventricle.
  • Other valvular (heart valve) and myocardial (heart muscle) structural diseases
  • Cardiomyopathies (diseases of the heart muscle) - e.g. dilatation (stretching and enlargement of the chambers) or hypertrophy.
  • Arrhythmias (abnormal heart rhythms)
  • Pericardial disease
  • Cor pulmonale - right ventricular heart failure secondary to chronic lung disease, e.g. chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bronchiectasis (permanent widening of the airways).
  • High-output states - when the body’s demands become excessive, the heart has to produce a grossly raised cardiac output and can eventually fail, for example in sepsis, severe anaemia or thyrotoxicosis (too much thyroid hormone).

 

A main cause of heart failure is a reduction in stroke volume (SV). The causes of this can be split into three categories:

  • Reduced pre-load - less filling of the ventricles (pre-load is the stretch on the ventricle as it fills), so less blood is pumped out. Once heart failure is established, fluid retention raises pre-load instead (see Pathophysiology).
  • Reduced myocardial activity - heart muscle can no longer produce the same force of contraction for a given volume so less blood is pumped out.
  • Increased after-load - the heart is pumping against a higher pressure leading to hypertrophy.

 

Heart Failure Classification

Heart failure is classified by its ejection fraction, which is worked out from this equation:

Ejection fraction = (Stroke Volume) / (End Diastolic Volume). Ejection fraction is therefore the proportion of the blood in the ventricle at the end of filling that is pumped out with each beat. NICE defines three groups. Heart failure with reduced ejection fraction means an ejection fraction of 40% or less. Heart failure with mildly reduced ejection fraction means 41% to 49%. Heart failure with preserved ejection fraction means 50% or more, together with at least two structural changes in the heart on echocardiography (an ultrasound scan of the heart), such as an enlarged left atrium or a thickened wall of the left ventricle.

The two main types, at either end of the ejection fraction range, are:

  • Heart failure with reduced ejection fraction, HFrEF - where there is systolic dysfunction.
    • In HFrEF, there is a problem with heart contraction and therefore the heart cannot pump with enough force, so there is systolic dysfunction.
    • Causes include: thin/fibrosed walls, enlarged chambers, abnormal/uncoordinated contraction.
    • It is also known as systolic heart failure.
  • Heart failure with preserved ejection fraction, HFpEF - where there is diastolic dysfunction.
    • In HFpEF, there is a problem with the heart where it does not fill properly, so there is diastolic dysfunction.
    • One cause of diastolic dysfunction is hypertrophy (thickening of the heart muscle). Hypertrophy makes the chambers stiff, so they cannot relax enough to allow adequate filling of the ventricles. 

 

Heart Failure Classification SimpleMed

Diagram - The classification of heart failure

SimpleMed original by Dr. Bethany Turner 

 

Heart failure can also be classified based on the symptoms that patients experience, using the New York Heart Association (NYHA) classification. The classes are:

  • Class I - no symptomatic limitation of physical activity.
  • Class II - slight limitation of physical activity. No symptoms at rest.
  • Class III - marked limitation of physical activity. No symptoms at rest.
  • Class IV - inability to carry out any physical activity without symptoms. Symptoms are present at rest.

Heart failure on one side of the heart can lead to heart failure on the other side of the heart. When there is both left and right sided heart failure, this is called biventricular heart failure. NICE Clinical Knowledge Summaries (CKS), the NICE summaries written for primary care, note that the older terms "congestive heart failure" (heart failure with sodium and water retention), "left heart failure" and "right heart failure" are potentially misleading and no longer routinely used. This article still uses left and right sided heart failure to describe patterns of symptoms and signs.

 

Pathophysiology

Pathophysiology means how a disease disturbs the body’s normal workings. In heart failure the decreased cardiac output (CO) causes a decreased blood pressure (BP). BP = CO x TPR, where TPR is total peripheral resistance, the resistance to blood flow in the blood vessels. Reduced BP causes:

  • Baroreceptors (pressure sensors in the artery walls) to detect the low BP and stimulate an increased sympathetic drive that leads to:
    • Increased heart rate
    • Increased peripheral resistance
  • Activation of the Renin-Angiotensin-Aldosterone System (RAAS, a hormone system that raises blood pressure) that causes:
    • Increased sodium retention leading to increased water retention (water follows sodium) and this increases the circulating volume
    • Anti-Diuretic Hormone (ADH) release, which makes the kidneys keep water
    • Vasoconstriction
    • Enhanced sympathetic activity

Together, these responses are an attempt to increase BP, but in reality they end in increased after-load and pre-load, placing even more strain on the failing heart.

 

Signs and Symptoms of Heart Failure

The signs and symptoms of heart failure depend on the side of the heart affected. This determines whether the pulmonary or systemic circulation is predominantly affected. 

Right sided heart failure signs and symptoms:

  • Fatigue/lethargy
  • Breathlessness
  • Peripheral pitting oedema (swelling that leaves a dent when pressed)
  • Raised jugular venous pressure (the pressure in the neck veins is higher than normal)
  • Tender, smooth and enlarged liver (hepatomegaly)

Left sided heart failure signs and symptoms:

  • Fatigue/lethargy
  • Breathlessness
  • Pulmonary oedema which can manifest as:
    • Orthopnoea (breathlessness on lying flat)
    • Paroxysmal nocturnal dyspnoea - attacks of breathlessness at night that wake the patient from sleep
    • Basal pulmonary crackles (crackling sounds heard with a stethoscope at the lung bases)
  • Cardiomegaly (an enlarged heart). An enlarged left ventricle displaces the apex beat (the lowest and outermost point where the heartbeat can be felt) on examination.

 

Investigations for Heart Failure

Full Blood Count - check for anaemia as the symptoms of anaemia are similar to heart failure. Anaemia can worsen heart failure as it puts further strain on the heart to meet the body's demands. 

Electrolytes and renal function - advanced chronic kidney disease can cause fluid overload because the kidneys do not remove enough fluid from the body. Fluid overload can cause the symptoms of heart failure. NICE also advises measuring renal function and electrolyte levels before starting, and regularly while taking, heart failure medicines that can affect them (see Management).

B-type (brain) Natriuretic Peptide (BNP) - BNP is produced by the stretching of ventricles. It is produced to try and reduce BP by increasing sodium loss and therefore increasing water loss. In the UK, NICE advises measuring N-terminal pro-B-type natriuretic peptide (NT-proBNP, a related peptide also released when the ventricles are stretched) in people with suspected heart failure.

  • A raised level supports the diagnosis of heart failure but does not confirm it. In suspected chronic heart failure, an NT-proBNP of less than 400 nanogram/litre in an untreated person makes the diagnosis less likely. In new suspected acute heart failure, NICE uses a BNP of less than 100 nanogram/litre or an NT-proBNP of less than 300 nanogram/litre to rule out the diagnosis. Obesity, African or African-Caribbean ethnic background and some heart failure medicines can lower the level. Other conditions, for example kidney disease or chronic obstructive pulmonary disease, can raise it.
  • The NT-proBNP level helps to decide how soon a person needs specialist assessment and echocardiography (an ultrasound scan of the heart). NICE advises referral within 2 weeks for an NT-proBNP above 2,000 nanogram/litre, and within 6 weeks for 400 to 2,000 nanogram/litre. Very high levels carry a poor prognosis.

ECG - NICE advises a 12-lead ECG (a recording of the heart’s electrical activity) in suspected heart failure. It is done alongside other tests that look for aggravating factors and alternative diagnoses, and it does not diagnose heart failure on its own.

Chest X-Ray - pulmonary oedema can be classically seen on a chest X-ray as batwing shadowing (white shadowing that spreads out from the centre of both lungs, like the wings of a bat). An enlarged heart can also be seen as an increased cardiothoracic ratio. This is the maximal horizontal diameter of the heart divided by the maximal horizontal diameter of the thorax (chest) on the X-ray.

Echocardiogram - can be used to measure the ejection fraction to help determine the type of heart failure. It can also assess the valve and ventricular function to help determine the causative factor. 

Coronary angiography - this technique is an X-ray scan of the coronary arteries after injecting contrast dye. It shows whether the arteries are blocked by an atherosclerotic plaque (a fatty deposit in the artery wall). If there is a blockage of a coronary artery, the oxygen delivery to the myocardium is reduced, putting strain on the heart. Blockage can lead to ischaemia and acute coronary syndromes (sudden reduced blood flow to the heart muscle, such as a heart attack).

 

Management of Heart Failure

Management of heart failure depends on whether it is acute or chronic.

Acute heart failure is managed in hospital in the following way:

  • Give oxygen if the patient is hypoxaemic (has a low blood oxygen level).
  • Give an IV loop-diuretic (a strong diuretic, a drug that makes the kidneys pass more urine), furosemide. This causes diuresis (water loss) to reduce the volume of fluid in the circulation. This will reduce pre-load and can improve cardiac output.
    • Giving a diuretic also helps to reduce oedema.
  • Consider heparin (an anticoagulant, a drug that reduces blood clotting) if there is another indication, such as atrial fibrillation (an irregular, often fast heart rhythm), venous thromboembolism (a blood clot in a vein) or acute coronary syndrome. Heparin is also used to prevent venous thromboembolism: NICE advises offering this prevention for at least 7 days to acutely ill medical patients whose risk of clots outweighs their risk of bleeding.
  • Ventilator support is not used routinely. Consider non-invasive ventilation without delay. This is breathing support through a mask, such as CPAP (continuous positive airway pressure). It is used when there is pulmonary oedema with severe breathlessness and acidaemia (too much acid in the blood). Consider invasive ventilation (a breathing tube) if respiratory failure, reduced consciousness or exhaustion develops.
  • IV nitrates (drugs that widen blood vessels) are not offered routinely. They are used in specific circumstances, such as myocardial ischaemia, severe hypertension, or regurgitant (leaking) aortic or mitral valve disease.

Chronic heart failure is managed by:

  • Treating the underlying cause and, where needed, surgery or devices:
    • E.g. surgery to repair or replace a damaged heart valve.
    • A pacemaker (a small device that sends electrical signals to help control the heartbeat) is used for some heart rhythm problems, such as a slow heartbeat. An implantable cardioverter defibrillator (ICD, a device that shocks the heart out of a dangerous rhythm) is another device. Cardiac resynchronisation therapy (CRT, a pacemaker that helps the ventricles contract together) is a further option. NICE recommends ICDs and CRT as options for selected people with heart failure and a left ventricular ejection fraction of 35% or less, chosen according to their symptoms and ECG findings.
    • In severe heart failure, a left ventricular assist device (a mechanical pump that helps the heart pump blood) or a heart transplant may be offered.
  • Non-pharmacological management:
    • NICE advises offering a personalised, exercise-based cardiac rehabilitation programme, which also includes psychological and educational support.
    • NICE advises against routinely restricting salt or fluid. Ask about intake and reduce it if it is high. Restrict fluid for dilutional hyponatraemia (a low blood sodium level caused by too much water). Avoid salt substitutes that contain potassium, because they can raise the blood potassium level, especially alongside ACE inhibitors and MRAs.
    • Cut down on alcohol and stop smoking, because both can damage the heart and blood vessels. NICE advises offering an annual influenza vaccination and a once-only pneumococcal vaccination (protection against a common cause of pneumonia), because chest infections can make heart failure worse.
  • Pharmacological therapy (drug treatment) - this relieves symptoms and, for several of the drugs below, reduces hospital admissions and deaths.
    • For heart failure with reduced ejection fraction, NICE advises offering a combination of four medicines. The order and timing of starting each one depend on the person. The four are an ACE (angiotensin-converting enzyme) inhibitor, a β-blocker (a drug that slows the heart and reduces its workload), a mineralocorticoid receptor antagonist (MRA, such as spironolactone, which blocks the action of aldosterone) and an SGLT2 inhibitor (a sodium-glucose cotransporter-2 inhibitor, which makes the kidneys pass more glucose into the urine).
    • If someone has symptoms of intolerance to an ACE inhibitor that are not angioedema (swelling of the face, lips or throat), NICE advises offering an angiotensin receptor-neprilysin inhibitor (ARNI) in its place, together with the other three medicines. An ARNI is a combination drug, for example sacubitril with valsartan, that blocks angiotensin II receptors and also stops the breakdown of natriuretic peptides (hormones that help the body lose salt and water). An ARNI is not used after angioedema with an ACE inhibitor. After angioedema with an ACE inhibitor, or if an ARNI is not tolerated, NICE advises offering the other three medicines and considering an angiotensin II receptor blocker (ARB), with caution if there has been angioedema. If symptoms continue despite the maximum tolerated dose of each of the four medicines, NICE suggests considering a switch from the ACE inhibitor to an ARNI. Allow at least 36 hours between the last ACE inhibitor dose and the first ARNI dose, because of the risk of angioedema. Primary care prescribers should consider seeking advice from a heart failure specialist before starting an ARNI.
    • For mildly reduced ejection fraction, NICE advises considering the same four medicines. For preserved ejection fraction, NICE advises considering an MRA and an SGLT2 inhibitor. For both mildly reduced and preserved ejection fraction, finerenone (a newer MRA) is also recommended as an option (NICE guidance TA1182, 2026).
    • Diuretics relieve congestive symptoms and fluid retention. NICE advises using the lowest dose that works, adjusted up or down according to need.
    • In heart failure with reduced ejection fraction, NICE advises checking iron status with blood tests, including serum ferritin (a measure of the body’s iron stores) and haemoglobin. Intravenous (IV) iron can be considered if there is iron deficiency and the haemoglobin is below 150 g per litre.
    • The aims of pharmacological therapy are to relieve symptoms, reduce admissions to hospital and improve survival. Several of these drugs act on the hormonal and sympathetic responses described in Pathophysiology. For example, MRAs block the action of aldosterone.

 

Edited by: Dr. Ben Appleby

Reviewed by: Dr. Marcus Judge

Quiz

Preview the Heart Failure quiz